The merger is proceeding as planned with management actively soliciting shareholder support. Monitor for the filing of the definitive proxy statement and the shareholder vote date. The deal is likely to close given AbbVie's resources and the strategic fit, but watch for any regulatory delays or competing bids. APGE stock should trade near the deal price until close.
APGE drugs
APGE drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 29 $132.61entry
- T+1 · 5mo ago +0.09%α −0.69% · $132.73
- T+5 · 4mo ago +0.67%α −0.72% · $133.50
- T+20 · 4mo ago +1.26%α +1.54% · $134.28
- T+60 · due 8w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) in support of its proposed acquisition by AbbVie, including a principal investigator email urging shareholder approval. The merger, announced on June 22, 2026, is expected to close in Q3 2026, subject to customary conditions including shareholder and regulatory approvals. This filing confirms management's active solicitation and commitment to the deal.
Key Financial Metrics
Key Facts
- Merger agreement with AbbVie dated June 18, 2026, via a merger subsidiary structure
- Transaction expected to close in Q3 2026, subject to shareholder approval and regulatory clearances
- Management is actively soliciting proxies in favor of the merger via a principal investigator email
- Apogee's lead asset is zumilokibart (APG777), a potential treatment for inflammatory and immunological conditions
- Deal rationale: AbbVie's global immunology infrastructure to accelerate pipeline development and patient reach
Financial Impact
Acquisition premium not disclosed in this filing; Apogee's market cap is approximately $10.0B
Risk Factors
- Failure to obtain shareholder approval or regulatory clearance could delay or terminate the merger
- Potential competing acquisition proposals or antitrust concerns
- Clinical or regulatory setbacks for zumilokibart could affect deal valuation or closing conditions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-026601 |
| Document: 0001140361-26-026601-index-headers.html | 0001140361-26-026601 |
| Document: 0001140361-26-026601-index.html | 0001140361-26-026601 |
| Document: 0001140361-26-026601.txt | 0001140361-26-026601 |
Track record
31 reports on APGE
8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Viewing Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers